What Counts as a Good Biomarker Study?

A good biomarker study does more than show that a marker changes. It should clearly define what the biomarker is meant to represent, measure it reliably, and show why the observed change is meaningful for the outcome being discussed. This is especially important in longevity research, where biomarker claims are often treated as proxies for healthspan or lifespan. [1] [2] [3]

1. Start With the Biomarker's Intended Use

Biomarkers can be used for different purposes: risk prediction, disease detection, pharmacodynamic response, prognosis, or surrogate endpoints. A study should state which role the biomarker is supposed to play. Standards for evidence differ across these use cases. [1]

A marker used for short-term mechanistic monitoring is not automatically suitable as a surrogate for long-term healthspan or mortality outcomes. [1] [2] [3]

2. Check Analytical Validity (Can It Be Measured Reliably?)

Good studies describe how samples were collected, processed, and analyzed, and whether assay performance is stable across batches, operators, and time. Without measurement reliability, associations may be noisy or misleading. [1] [4]

Useful details include reproducibility, calibration, quality control procedures, and handling of missing values or outliers. [4] [5]

3. Check Clinical or Biological Relevance (Does It Matter?)

A biomarker can be measured accurately and still have limited value if it is weakly related to the outcome of interest. Stronger biomarker studies connect measurements to relevant clinical, functional, or disease outcomes and explain the biological rationale for the relationship. [1] [2] [6]

In ageing research, many biomarkers are promising but remain exploratory. That does not make them useless, but it should limit the strength of claims made from them. [2] [3]

4. Study Design Still Matters

Biomarker quality cannot be separated from study design quality. A precise biomarker measured in a small, biased, or poorly controlled study may still produce unreliable conclusions. Trials, cohort studies, and case-control studies each answer different questions and require different interpretations. [7] [8] [9]

Readers should check sample size, participant selection, confounder adjustment, and whether analyses were prespecified. Overfitting and selective reporting are common risks in biomarker-heavy research. [5] [8] [10]

5. Validation and Replication Are Essential

A strong biomarker study usually includes internal validation, external validation, or independent replication. Findings that work only in one dataset may reflect noise, batch effects, or idiosyncratic population characteristics. [5] [10]

For predictive biomarkers or biomarker-based models, transparent reporting and validation frameworks (such as TRIPOD and related risk-of-bias tools) help readers judge whether results are robust enough for broader use. [5] [10] [11]

6. Watch for Surrogate Endpoint Overreach

A biomarker change may indicate target engagement or physiological change without proving a clinical benefit. Good reporting distinguishes between biomarker improvement and demonstrated improvement in health outcomes. [1] [3]

In longevity contexts, this distinction is critical because long-term outcomes are difficult to measure and surrogate claims can easily be overstated. [2] [3]

7. Practical Checklist for Readers

• What is the biomarker intended to represent or predict?
• How was it measured, and is the assay method described clearly?
• What outcome is it being linked to: mechanism, risk, function, disease, or mortality?
• What is the study design and sample size?
• Were confounders handled appropriately?
• Was there validation or replication?
• Are conclusions framed as exploratory, predictive, or clinically established?

Summary

A good biomarker study combines a clear intended use, reliable measurement, relevant outcomes, sound study design, and validation. In longevity science, where biomarker claims are common, this helps distinguish useful signals from premature conclusions. [1] [5] [10]

References

1. BEST (Biomarkers, EndpointS, and other Tools) Resource. FDA-NIH Biomarker Working Group.
2. Jylhävä J, Pedersen NL, Hägg S. Biological Age Predictors. Frontiers in Medicine (2018).
3. Justice JN, et al. Frameworks for proof-of-concept clinical trials of interventions that target fundamental aging processes. Journals of Gerontology A (2018).
4. Lee JW, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharmaceutical Research (2006).
5. Collins GS, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD). BMJ (2015).
6. National Institute on Aging (NIA): Geroscience and the intersection of aging biology and chronic disease.
7. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement. BMJ (2010).
8. von Elm E, et al. STROBE statement. PLoS Medicine (2007).
9. Sterne JA, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (2016).
10. Ioannidis JPA. Why Most Published Research Findings Are False. PLoS Medicine (2005).
11. Wolff RF, et al. PROBAST: A Tool to Assess Risk of Bias and Applicability of Prediction Model Studies. BMJ (2019).